ICBT for Psychological Symptoms Related to the COVID-19 Pandemic Remaining After Societal Opening
Launched by LINKOEPING UNIVERSITY · Dec 16, 2022
Trial Information
Current as of January 14, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The study is a randomized controlled trial about the effects of ICBT regarding psychological symptoms related to the COVID-19 pandemic and its consequences remaining after societal opening. Primary outcome measures are depression symptoms (measured with Beck Depression Inventory-II) and anxiety symptoms (measured with Generalized Anxiety Disorder-7). Other outcome measures used will for example be about stress symptoms, sleep problems, post traumatic stress symptoms and quality of life.
Because of uncertainties about the psychological effects of COVID-19 pandemic, a transproblematic indivi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Experience mental health problems related to the COVID-19 pandemic and/or its consecuences, which are still experienced as a problem (when the pandemic is not considered as dangerous to the society)
- • 18 years or older
- • Adequate ability to speak, read and write in Swedish
- • Having access to the internet and a smartphone, computer or other device
- Exclusion Criteria:
- • Severe psychiatric or somatic issues that makes participation harder or impossible (which can include the diagnosis postcovid)
- • Ongoing addiction
- • Acute suicidality
- • Other ongoing psychological treatment
- • Recent (within the past 3 months) changes in the dose of psychotropic medication or planned change during the treatment weeks
Trial Officials
Gerhard Andersson, PhD
Principal Investigator
Linkoeping University
About Linkoeping University
Linköping University is a leading academic institution in Sweden, renowned for its innovative research and commitment to advancing medical science. With a strong emphasis on interdisciplinary collaboration, the university facilitates cutting-edge clinical trials aimed at improving patient outcomes and enhancing healthcare delivery. Linköping University’s research initiatives are supported by state-of-the-art facilities and a robust network of partnerships with healthcare providers, industry stakeholders, and regulatory bodies, ensuring rigorous methodologies and ethical standards in all clinical investigations. Through its dedication to research excellence, Linköping University plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Linköping, östergötland, Sweden
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials